Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug. Hours after Hims & Hers posted a blog ...

Eli Roth‘s The Horror Section has acquired “Jimmy and Stiggs,” marking the horror company’s first major deal since launching earlier this month, Variety can exclusively report. Directed ...

Reserve your spot now. Eli Lilly And Co LLY, on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the ...

Popular comedian Shane Gillis is headed to Cleveland this month. He will make a stop to Rocket Arena as a part of his ongoing "Shane Gillis Live" tour. "The highly-anticipated tour, in partnership ...

Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here. Eli Lilly and Co. has begun selling its blockbuster ...

Eli Lilly (NYSE:LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass compounding its blockbuster GLP-1/GIP receptor agonist tirzepatide. Tirzepatide is ...

By Borys Kit Senior Film Writer There will be blood. And probably lots of it. Filmmaker Eli Roth has launched The Horror Section, a new, all-encompassing horror media company that aims not just to ...

US-based pharmaceutical giant Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, following approval from the Central Drugs Standard Control Organisation (CDSCO).

You want to stay comfortable while still getting the storage space you need. Lightweight backpacks are designed to keep the wearer comfortable and provide well-organized space for everything you ...

Information About Us Contact us Feedback Terms Of Service Privacy Policy Subscriber Agreement JPost Jobs Cancel Subscription Sitemap Customer Service JP Store ...

Eli Lilly is developing what could be the first oral GLP-1 agonist. Late-stage clinical trial data is coming this year. The stock has a steep valuation despite trading sideways since the summer ...

“Semaglutide generics will be priced almost 95% lower than [Eli Lilly'] current price,” said Vishal Manchanda, senior vice-president, institutional research at Systematix Group. With the drop ...